Physician profile
Marcus A Earle
NPI 1417290255
$2,794.19
in general payments reported to CMS, 2019-2025
53 companies · $641 in 2025
The $641 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $228 · 2021: $313 · 2022: $416 · 2023: $306 · 2024: $462 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268.13 | 2019-2025 | Rinvoq |
| Glaxosmithkline, LLC. | $206.44 | 2020-2023 | Shingrix, Arexvy |
| Grifols USA, LLC | $187.96 | 2019-2025 | Gamunex-C |
| Novo Nordisk INC | $185.76 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $177.88 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Biotech, INC. | $141.06 | 2019-2024 | Tremfya |
| Lundbeck LLC | $114.43 | 2022-2025 | Vyepti |
| Actelion Pharmaceuticals US, INC. | $101.83 | 2021-2023 | Opsumit |
| Astrazeneca Pharmaceuticals LP | $99.65 | 2019-2025 | Airsupra |
| Madrigal Pharmaceuticals | $81.57 | 2025 | Rezdiffra |
| Pfizer INC. | $68.57 | 2019-2025 | |
| Lilly USA, LLC | $67.97 | 2023-2024 | Mounjaro |
| Alexion Pharmaceuticals, INC. | $65.44 | 2023-2024 | Ultomiris |
| Allergan, INC. | $53.68 | 2019-2020 | |
| Radius Health, INC. | $53.25 | 2024-2025 | Tymlos |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Earle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.